Tango Therapeutics (NASDAQ:TNGX) & ImageneBio (NASDAQ:IMA) Critical Contrast

ImageneBio (NASDAQ:IMA) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Profitability

This table compares ImageneBio and Tango Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-32.61%	-29.43%
Tango Therapeutics	N/A	-35.41%	-32.70%

Volatility & Risk

ImageneBio has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for ImageneBio and Tango Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2	0	1	0	1.67
Tango Therapeutics	2	2	13	0	2.65

ImageneBio currently has a consensus price target of $28.00, indicating a potential upside of 634.91%. Tango Therapeutics has a consensus price target of $45.54, indicating a potential upside of 87.40%. Given ImageneBio’s higher possible upside, equities analysts plainly believe ImageneBio is more favorable than Tango Therapeutics.

Institutional and Insider Ownership

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 2.2% of ImageneBio shares are owned by insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares ImageneBio and Tango Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800,000.00	54.05	-$45.35 million	($4.58)	-0.83
Tango Therapeutics	$62.38 million	65.68	-$101.59 million	($0.85)	-28.59

ImageneBio has higher earnings, but lower revenue than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Summary

Tango Therapeutics beats ImageneBio on 8 of the 13 factors compared between the two stocks.

About ImageneBio

ImageneBio, Inc. is a biotechnology company focused on advancing precision oncology through blood-based molecular testing and data analysis. The company develops technologies designed to help identify and monitor cancer-related genomic signals using liquid biopsy samples. Its platform is intended to support the detection and tracking of tumor biomarkers, potentially helping clinicians assess treatment response, identify disease progression, and guide more personalized cancer-care decisions. ImageneBio combines molecular analysis with computational tools to translate circulating biological information into insights for oncology research and clinical use.

About Tango Therapeutics

Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.